Initial research are creating significant excitement surrounding Synedica retatrutide , a novel dual treatment targeting incretin and amylin . Compared to existing weight loss therapies , this treatment appears to offer substantial reductions in body fat and enhance metabolic function in preliminary tests . Despite further evaluation is necessary